A simple cheek swab could one day offer a rapid, non-invasive way to diagnose schizophrenia, according to new research from Rutgers University in New Jersey. The potential for a quicker diagnosis is significant, as early intervention is often crucial for managing the condition and improving patient outcomes.
A study published in Science Advances revealed higher levels of two biological markers in cheek swabs taken from individuals with schizophrenia compared to those without the mental health disorder. Schizophrenia is a chronic condition characterized by a range of symptoms, including hallucinations, delusions, disorganized thinking, and a diminished interest in daily activities.
Â
Challenges in Diagnosing the Disorder
Â
Currently, there is no single test to definitively diagnose schizophrenia. The diagnostic process can be complex, as symptoms vary considerably from person to person, and typically relies on observing a patient’s behavior over time. This can sometimes take months, delaying appropriate treatment whereas doctors rule out other potential causes.
To address this challenge, researchers investigated whether molecular signatures in easily collected cheek cells – also known as buccal cells – could serve as reliable biomarkers.
The study involved 27 individuals diagnosed with schizophrenia and 27 healthy volunteers as a control group, carefully matched for age, race, and gender. Researchers collected samples from the inside of each participant’s cheek.
These samples were analyzed to measure the amount of RNA to assess the activity of specific genes. The research team focused on three genes previously linked to an increased risk of developing schizophrenia. They then used mass spectrometry to determine if any related proteins differed between the patient and control groups.
Â
Key Findings
Â
Individuals with schizophrenia exhibited significantly higher activity levels in the Sp4 gene compared to the control group. This gene plays a role in brain development, and elevated activity levels were associated with more severe symptoms, such as hallucinations and delusions.
Researchers suggest these markers may be effective because the central nervous system and the oral mucosa develop from the same embryonic tissue, meaning cheek swabs could provide insights into what is happening in the brain.
While the findings are promising, larger studies are needed to confirm whether these biomarkers are specific to schizophrenia. If successful, a simple swab could not only aid in early detection but also help monitor the progression of the illness.
Â
